MTOR, the target of rapamycin, is often upregulated in a variety of cancers, while rapamycin is extremely selective in blocking MTOR. Interestingly, our case study pinpointed MTOR correctly and made our pathway enrichment method conceivable in the study of breast cancer. Here, MTOR is linked to cancer.